Skip to search formSkip to main contentSkip to account menu

ICRF-159

Known as: ICI 59118, ICRF 159, ICRF159 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

razoxane

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1990
1990
Prevention of cumene hydroperoxide induced oxidative stress in cultured neonatal rat myocytes by scavengers and enzyme inhibitors.
1985
1985
Comparison of the protective effect of ICRF-187 and structurally related analogues against acute daunorubicin toxicity in Syrian golden hamsters.
1983
1983
Inhibition of cardiotoxic, nephrotoxic and neurotoxic effects of doxorubicin by ICRF-159.
Cardiotoxicity of doxorubicin, 2 mg/kg i.p. twice weekly in rats, was assessed by serial electrocardiography and electron… 
1981
1981
Studies in mice treated with ICRF-159 combined with daunorubicin or doxorubicin.
We have investigated the effect of ICRF-159 on the toxicity of daunorubicin (DR) and doxorubicin (DX) given iv, and the… 
1980
1980
Further experience with rezoxane (ICRF 159; -- NSC --129943) in treating Kaposi's sarcoma.
47 patients with histologically proven Kaposi's sarcoma were treated with multiple courses of Rezoxane (each course: 1 g/m2/day… 
1979
1979
Combination of radiotherapy and razoxane (ICRF 159) for chondrosarcoma
Eight patients with 12 chondrosarcomas were treated with radiation and razoxane (ICRF 159). Two tumors in 1 patient progressed… 
1977
1977
Study of trans-cyclopropylbis (diketopiperazine) and chelating agents related to ICRF 159. Cytotoxicity, mutagenicity, and effects on scheduled and unscheduled DNA synthesis.
The cytotoxicity, mutagenicity, and DNA damaging potential of trans-cyclopropylbis (diketopiperazine) (3) and chelating agents… 
1975
1975
The Effects of an Antimetastatic Agent, (±)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane (ICRF 159), on Platelet Behavior
: Some agents that inhibit platelet aggregation, e.g., aspirin and dipyridamole, ahve been reported to prevent metastasis… 
1974
1974
Synergism of ICRF 159 and radiotherapy in treatment of experimental tumors
ICRF 159, an antimitotic agent that increases the antitumor activity of most antineoplastic drugs, has now also been shown to… 
1974
1974
Combined treatment of soft tissue and osteosarcomas by radiation and ICRF 159
In a pilot clinical assessment of combined radiotherapy with the antimitotic agent ICRF 159, a good response was obtained in 18… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)